Michael Thomas Heffernan insider trades: Trevi Therapeutics (TRVI) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michael reports to the SEC
and 5 more companies
Open-market buys and sales
26 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | TRVI | ↓ Sell10b5-1 | 39,373 | $15.09 | $594K | Direct | Sep 17, 2026 (2d) |
| Dec 27, 2022 | COLL | ↓ Sell | 25,041 | $23.58 | $590K | Direct | Dec 27, 2022 (0d) |
| Dec 21, 2022 | COLL | ↓ Sell | 83,964 | $23.09 | $1.9M | Direct | Dec 21, 2022 (0d) |
| Dec 13, 2022 | COLL | ↓ Sell | 189,607 | $22.14 | $4.2M | Direct | Dec 14, 2022 (1d) |
| Mar 15, 2021 | COLL | ↓ Sell | 50,075 | $25.30 | $1.3M | Direct | Mar 17, 2021 (2d) |
| Aug 11, 2020 | COLL | ↓ Sell | 13,071 | $19.13 | $250K | Direct | Aug 12, 2020 (1d) |
| May 13, 2020 | COLL | ↓ Sell | 19,254 | $21.63 | $416K | Direct | May 15, 2020 (2d) |
| Jan 21, 2020 | COLL | ↓ Sell | 295,287 | $21.93 | $6.5M | Direct | Jan 22, 2020 (1d) |
| Jul 15, 2019 | COLL | ↓ Sell | 25,000 | $11.26 | $282K | Direct | Jul 17, 2019 (2d) |
| Jun 17, 2019 | COLL | ↓ Sell | 25,000 | $11.37 | $284K | Direct | Jun 19, 2019 (2d) |
| May 15, 2019 | COLL | ↓ Sell | 25,000 | $12.84 | $321K | Direct | May 17, 2019 (2d) |
| May 9, 2019 | TRVI | ↑ Buy | 2,500 | $10.00 | $25K | Direct | May 13, 2019 (4d) |
| Apr 15, 2019 | COLL | ↓ Sell | 25,000 | $15.09 | $377K | Direct | Apr 17, 2019 (2d) |
| Mar 15, 2019 | COLL | ↓ Sell | 25,000 | $17.17 | $429K | Direct | Mar 19, 2019 (4d) |
| Feb 15, 2019 | COLL | ↓ Sell | 25,000 | $14.81 | $370K | Direct | Feb 20, 2019 (5d) |
| Jan 15, 2019 | COLL | ↓ Sell | 25,000 | $15.56 | $389K | Direct | Jan 17, 2019 (2d) |
| Dec 17, 2018 | COLL | ↓ Sell | 25,000 | $18.18 | $454K | Direct | Dec 18, 2018 (1d) |
| Nov 15, 2018 | COLL | ↓ Sell | 25,000 | $16.60 | $415K | Direct | Nov 16, 2018 (1d) |
| Oct 15, 2018 | COLL | ↓ Sell | 25,000 | $16.53 | $413K | Direct | Oct 17, 2018 (2d) |
| Jun 12, 2018 | COLL | ↓ Sell | 150,000 | $25.27 | $3.8M | Direct | Jun 13, 2018 (1d) |
| May 10, 2018 | COLL | ↓ Sell | 7,100 | $26.21 | $186K | Direct | May 14, 2018 (4d) |
| Apr 19, 2018 | COLL | ↓ Sell | 44,400 | $26.00 | $1.2M | Direct | Apr 23, 2018 (4d) |
| Jan 23, 2018 | COLL | ↓ Sell | 16,408 | $25.01 | $410K | Direct | Jan 23, 2018 (0d) |
| Jan 22, 2018 | COLL | ↓ Sell | 3,592 | $25.00 | $90K | Direct | Jan 23, 2018 (1d) |
| Jan 19, 2018 | COLL | ↓ Sell | 20,000 | $22.50 | $450K | Direct | Jan 19, 2018 (0d) |
| Nov 15, 2017 | COLL | ↓ Sell | 50,000 | $15.53 | $777K | Direct | Nov 17, 2017 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Michael Thomas Heffernan's insider trades
Michael Thomas Heffernan is an insider at Trevi Therapeutics (TRVI). Since Nov 15, 2017, Michael has reported 1 open-market purchase worth $25K and 25 sales worth $26.3M on SEC Form 4. In the last 12 months: 1 sale ($594K).
1 sale (2% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (77 filings), shares withheld for taxes (14 filings), option exercises (8 filings), shares returned to the company (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TRVI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.